Prelude Therapeutics prices $100M public offering of common stock and pre-funded warrants

On May 18, 2023, Prelude Therapeutics Incorporated (“ Prelude ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Morgan Stanley & Co. LLC as representative (the “ Representative ”) of the underwriters named therein (the “ Underwriters ”), pursuant to which Prelude agreed to issue and sell an aggregate of (a) 4,496,744 shares of its common stock, which comprise (i) 3,048,522 shares of its voting common stock, par value $0.0001 per share (the “ Voting Common Stock ”) and (ii) 1,448,222 shares of its non-voting common stock, par value $0.0001 per share (the “ Non-Voting Common Stock ,” and together with the Voting Common Stock, the “ Shares ”), at a price to the public of $5.75 per share, and (b) pre-funded warrants to purchase up to 12,895,256 shares of the Company’s Voting Common Stock (the “ Pre-Funded Warrants ”), at a price to the public of $5.7499 per warrant with an exercise price of $0.0001 per share (the “ Offering ”).